Efficacy and Safety of Low‐Frequency Daratumumab Regimen in Systemic Light‐Chain Amyloidosis
ABSTRACT In recent years, daratumumab has been increasingly applied in the treatment of systemic light‐chain (AL) amyloidosis, significantly improving the prognosis of patients. Currently, the internationally recognized daratumumab treatment regimen comes from the ANDROMEDA trial. Given the low tumo...
Збережено в:
| Автори: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Wiley
2026-07-01
|
| Серія: | Cancer Medicine |
| Предмети: | |
| Онлайн доступ: | https://doi.org/10.1002/cam4.72103 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|